Shots:
- Eli Lilly has acquired Engage Biologics, combining Engage’s Tethosome platform with Lilly’s genetic medicines capabilities & portfolio
- As per the deal, Eli Lilly acquired Engage for ~$202M in cash, incl. an upfront payment and subsequent development milestones payments
- The Tethosome platform is a non-viral DNA delivery system that combines engineered DNA payloads, lipid nanoparticles, & mRNA-encoded tech to enhance localization & expression while improving the potency, tolerability, redosability, durability, & programmability of DNA-based therapies
Ref: Businesswire | Image: Engage Biologics | Press Release
Related News: Profluent Signs ~$2.25B Pact with Eli Lilly to Advance AI-Designed Recombinases for Genetic Medicines
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
